Tax

Unrecognized Tax Benefits Reevaluation (Statute Lapse)

Vertex Pharmaceuticals Unrecognized Tax Benefits Reevaluation (Statute Lapse) remained flat by 0.0% to $2.68M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 35.5%, from $4.15M to $2.68M. Over 2 years (FY 2023 to FY 2025), Unrecognized Tax Benefits Reevaluation (Statute Lapse) shows an upward trend with a 14.9% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementIncome Statement
SectionTax
CategoryRisk
SignalHigher is better
VolatilityStable
First reportedQ1 2023
Last reportedQ4 2025Feb 13, 2026

How to read this metric

A decrease indicates the removal of tax risk as the company is no longer liable for potential assessments on those specific historical positions.

Detailed definition

Represents the reduction in the liability for unrecognized tax benefits due to the expiration of the statute of limitati...

Peer comparison

Standard disclosure in the tax footnote for all companies subject to multi-jurisdictional tax audits.

Metric ID: isrg_unrecognized_tax_benefits_statute_lapse

Historical Data

3 years
 FY'23FY'24FY'25
Value$8.10M$16.60M$10.70M
YoY Change+104.9%-35.5%
Range$8.10M$16.60M
CAGR+14.9%
Avg YoY Growth+34.7%
Median YoY Growth+34.7%

Frequently Asked Questions

What is Vertex Pharmaceuticals's unrecognized tax benefits reevaluation (statute lapse)?
Vertex Pharmaceuticals (VRTX) reported unrecognized tax benefits reevaluation (statute lapse) of $2.68M in Q4 2025.
How has Vertex Pharmaceuticals's unrecognized tax benefits reevaluation (statute lapse) changed year-over-year?
Vertex Pharmaceuticals's unrecognized tax benefits reevaluation (statute lapse) decreased by 35.5% year-over-year, from $4.15M to $2.68M.
What is the long-term trend for Vertex Pharmaceuticals's unrecognized tax benefits reevaluation (statute lapse)?
Over 2 years (2023 to 2025), Vertex Pharmaceuticals's unrecognized tax benefits reevaluation (statute lapse) has grown at a 14.9% compound annual growth rate (CAGR), from $8.10M to $10.70M.
What does unrecognized tax benefits reevaluation (statute lapse) mean?
The reduction in tax liability reserves because the time limit for tax authorities to audit a past return has expired.